These findings lead us to conclude that an MMP-9 plasma level below 150 ng/ml at the time of cochlear implantation predisposes a child who has been diagnosed with DFNB1-related deafness to be a good performer, and is highly likely to reach full auditory development 18 months later. The gene discussed is MMP9; the disease is deafness.